Peptide science, referenced
A plain-language, referenced guide to peptide research
What the trials actually measured, what regulators approved and where, and how research peptides are tested. Every article is written from primary sources and lists them in full, with the figures drawn from the published data.
All articles 7
GLP-1 / GIP medicine
Tirzepatide: The Trials Behind the Approvals
How tirzepatide was designed, what the SURPASS and SURMOUNT trials measured, where regulators approved it, and the warnings printed on its label.
2026-09-17 · 15 min read
GLP-1 medicine
Semaglutide: SUSTAIN-6, STEP 1, SELECT and FLOW Explained
How semaglutide was designed for a weekly schedule, what four landmark trials measured, how its approvals grew, and the safety signals on its label.
2026-09-17 · 9 min read
Investigational
Retatrutide: Phase 3 Results and What Is Still Unknown
Retatrutide acts on three hormone receptors and is still investigational. What its phase 2 trial and the TRIUMPH phase 3 trials have reported so far.
2026-09-17 · 7 min read
Explainer
GLP-1 and GIP: The Gut Hormones Behind the New Medicines
What GLP-1 and GIP do in the body, why the natural hormones cannot be used as medicines, and how chemists made them last a week. A sourced history.
2026-09-17 · 7 min read
Research peptide
BPC-157: What the Published Evidence Contains
BPC-157 is widely discussed and approved nowhere. An inventory of its research: animal studies, three small human reports, and what regulators say.
2026-09-17 · 7 min read
Peptide medicine
Tesamorelin: A Peptide Approved for One Narrow Use
Tesamorelin is an approved analogue of growth hormone releasing factor with a single, narrow indication. Its trials, the limits on its label, and its warnings.
2026-09-17 · 6 min read
Explainer
How a Peptide Becomes an Approved Medicine
The path from laboratory to label: animal studies, three phases of human trials, review by the FDA and BPOM, and what an approval does and does not cover.
2026-09-17 · 9 min read